Bernd Goergen

Bernd Goergen is a Partner at High-Tech Gründerfonds (HTGF), based in Bonn, Germany, where Bernd leads early-stage investments for the firm's Life Sciences and Healthcare team.

Bernd's expertise spans seed-stage life sciences, biotech, and healthcare investments, and includes areas such as software, IT, digital business models, industrial tech, deep tech innovations, B2B SaaS platforms, artificial intelligence (AI), and the Internet of Things (IoT).

Holding a doctorate in virology, immunology, and human genetics from Johannes Gutenberg-Universität Mainz and certified as a Biotech Analyst, Bernd joined HTGF's Life Science Team in early 2008.

Bernd is instrumental in the entire investment lifecycle at HTGF, from deal sourcing and due diligence to leading investment rounds and providing strategic guidance to founders. Notably, Bernd accompanied the drug MYR from its preclinical stage to market as a seed investor, culminating in its acquisition by Gilead Sciences and becoming HTGF's first unicorn in 2021.

Prior to HTGF, Bernd's professional experience included five years in academic research, seven years in international diagnostics marketing, and extensive work in M&A and capital market deals within investment banking.

Currently, Bernd is focused on funding and fostering the next generation of German high-tech startups.

Bio is AI generated & may not be accurate.